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Aims: Macro-nutrient preloads given 30min before regular meals may improve
metabolism. The aim was to investigate how type 2 diabetic patients react to a preload
consisting of a blend of macro-nutrients with a low-glycemic index (Inzone Preload®).
Methods: In a before–after study design, 30 subjects with type 2 diabetes mellitus
(T2DM) were enrolled in a 12-week program. All subjects were given Inzone Preload (43%
proteins, 29% carbohydrates, 10% lipids, and 9% fibers, 71 kcal), 30min before each
meal during 12weeks. Fasting glucose and postprandial 2 h glucose were monitored
every second week. Body weight (BW) and waist circumference were measured each
month. Fasting plasma glucose, glycosylated hemoglobin, serum lipids, fasting insulin,
C-reactive protein, and homeostasis model assessment were evaluated before and after
the intervention. Subjective appetite was monitored using visual analogue scales after the
Inzone Preload.
Results: The dietary intervention significantly influenced several metabolic parameters
compared to base line. Inzone Preload treatment reduced mean postprandial plasma
glucose levels (12.21.2 vs. 10.52.0mmol/L), HbA1c (7.40.3 vs. 7.10.2%),
mean total cholesterol (4.80.9 vs. 4.30.8mmol/L), low-density lipoprotein cholesterol
(2.80.6 vs. 2.50.4mmol/L), and CRP (1.51.4 vs. 0.70.7mg/L). BW loss of more
than 3% was seen in 13 participants (43%). Feelings of satiety were significantly higher
after Inzone Preload than after habitual breakfast (p<0.05). No significant changes in
fasting blood glucose, high-density lipoprotein and total triacylglycerol, HOMA-IR, and
HOMA-β were observed.
Conclusion: A macro-nutrient preload treatment reduces postprandial glucose, inflam-
matory markers, and serum lipids in patients with T2DM. Approximately half of the study
group also displayed reduced BW.
Keywords: diabetes type II, nutrition, preload, human, glucose tolerance
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Introduction
Diabetes mellitus is a serious chronic disease threatening human
health. It is estimated that 382 million people worldwide are
affected and that the numbers will continue to increase to 471
million by 2035 (1). The prevalence of diabetes has increased
significantly in recent decades and is now reaching epidemic
proportions in China (2, 3). More recently, a study estimated
that the prevalence of diabetes is 11.6% and pre-diabetes affects
50.1% of the adult Chinese population (4). Therefore, the need for
further research on primary prevention and control of diabetes is
of paramount importance.
The majority of patients with impaired glycemic control do not
meet the recommended criteria for pharmacological treatment,
exposing them to risks of sustained hyperglycemia (2). There
is increasing evidence that postprandial hyperglycemia plays a
major role in the pathogenesis of diabetic macro-vascular com-
plications (5, 6). Therapeutic strategies to reduce postprandial
glucose are therefore of fundamental importance in the man-
agement of T2DM (7, 8). For patients with mild-to-moderate
hyperglycemia, postprandial blood glucose is a better predictor of
HbAlc than fasting blood glucose (FBG). Accordingly, pharma-
cological and dietary strategies to decrease postprandial glycemia
are receiving increased attention (9, 10). Major determinants of
postprandial blood glucose concentrations are the rate of gas-
tric emptying and the postprandial insulin response (6). There-
fore, modulation of gastric emptying and enhancement of insulin
effects to minimize dietary postprandial glucose elevation has a
potential to optimize glycemic control in diabetes. Over the past
two decades, diets based on foods that can reduce postprandial
blood glucose excursions have been investigated. Several studies
have demonstrated that low-glycemic index (GI) diets are useful in
the protection of diabetes (11–13), and low-GI foods are thought
to increase satiety by prolonging the availability of glucose in the
post-absorptive state and by producing a lower insulin response;
however, this association remains controversial (14).
In addition, research has also focused on the metabolic
responses to dietary proteins. Experimental studies have shown
that proteins, such as whey protein, reduce short-term appetite,
food intake, and attenuate blood glucose responses (15, 16). It
is speculated that dietary proteins enhance satiety and suppress
food intake in humans when consumed together with carbohy-
drates, and that this will reduce the subsequent glycemic response
(17). Previous studies indicate that the reduction in blood glu-
cose occurs because of digestion of proteins with a high content
of branched-chain amino acids (BCAAs) result in rapid insulin
release (15). As a result, research regarding the potential of BCAAs
to reduce the postprandial glycemic response and its health ben-
efits has received considerable attention. One promising strategy
to minimize postprandial glycemia could be a preload, in which
a small load of macro-nutrients, given at a fixed interval before a
meal, will induce the Incretin response. The release of peptides,
such as GLP-1, GIP, and cholecystokinin (CCK), will slow gas-
tric emptying and stimulate insulin secretion in advance of the
main nutrient load at ordinary meals. Studies have shown that
fat and protein preloads markedly reduce postprandial glycemic
excursions in patients with type 2 diabetes by such mechanisms
(18, 19).
However, preloads may potentially increase energy intake,
therefore preloads that entail minimal additional energy would
be advantageous. Based on the history of preloads used to treat
diabetes, we hypothesized that the Inzone Preload (a macronu-
trient and protein-enriched blend with low-GI) would reduce
postprandial glycemia in type 2 diabetic patients. To test this
hypothesis, we performed a clinical study, which aimed to explore
the potential effects of the Inzone preload on T2DM in Chinese
patients. Measurements were performed at both baseline and after
12-week follow-up. The primary purpose of this study was to
detect the effect of the Inzone Preload on glucosemetabolism. The
secondary objective was to assess bodyweight (BW), lipid profiles,
inflammation, insulin resistance, and appetite sensations.
Materials and Methods
Study Design
The study was designed as a before–after intervention study of
12-week duration with the Inzone Preload given 30min before
each of the three main meals. The study was carried out at the
Metabolic Disease Hospital, Tianjin Medical University. Subjects
were given written and oral information about the study and gave
their written consent to be part of the study. The Ethical Commit-
tee of the Tianjin Medical University approved the study as being
in accordance with the Helsinki II Declaration. To minimize the
potential confounding effects of different anti-diabetic medica-
tions, hypoglycemic agent dosages were not changed during the
study.
Study Subjects – Recruitment and Screening
Volunteers were recruited from endocrinology outpatient clin-
ics in Tianjin Medical University Metabolic Hospital. Of total,
19 men and 11 women aged 54.8 7.8 years with a BMI of
26.5 3.4 kg/m2 were enrolled in the present study. Participants
inclusion criteria were as follows: age>18 years, diagnosis of type
2 diabetes, hemoglobinA1c (HbA1c)9%, postprandial 2 h blood
glucose10.0mmol/L,management of their diabeteswith a stable
diet, and anti-diabetic medication stable for at least 2months.
Exclusion criteria were as follows: use of pre-meal insulin therapy,
any known chronic illnesses (such as liver and kidney disease),
allergy to beans or milk. Among the 30 subjects, 19 (63.3%) had
abdominal obesity (based on waist circumference), 17 (56.7%)
were overweight (BMI >24 kg/m2), and 14 (46.7%) had dyslipi-
demia. Additional characteristics of the study subjects included:
tobacco use 7 (23.3%), alcohol consumption 2 (6.7%), and exercise
14 (46.7%).
Subjects were interviewed concerning general health, personal
and family health history, eating and exercise habits to assess
eligibility, and data on BW, height, waist circumference, blood
pressure, and fasting biochemical markers were obtained. Partic-
ipants were screened using a phone or an in-person meeting. At
the initial visit and every 2weeks for the next 12weeks, FBG and
the postprandial 2 h blood glucose (2 h-BG) were measured. 2 h-
BG was measured after instructing the patient to consume a meal
containing calories calculated according to their BW. BW and
waist circumference were measured in 4weeks interval. Partici-
pants were documented regarding the Inzone Preload tolerance or
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adverse effects, medications consumed, physical activity, illnesses,
and any other information they thought was relevant.
The Inzone Preload
The Inzone Preload consists only of natural food ingredients (pea-
protein, whey protein, egg albumin, Ω 3/6 fatty acids, whole
eggs, apple, rosehip, and sugar beet fiber). Each serving of Inzone
Preload (18 g) contains 7.6 g protein, 1.8 g fat (saturated and
unsaturated fat are 0.6 and 2 g, respectively), 1.5 g fiber, and 5.2 g
carbohydrates, which provided 71 kcal energy (Indevex Biotech,
Sweden). Subjects were instructed to mix and shake one pack-
age of Inzone Preload powder with 150mL cold drinking water
and after 1–2min of hydration, to consume the preload 30min
before each meal in the study. The GI value of the preload was
<20, as recommended by Brouns et al. in their description of GI
methodology.
Anthropometric Measures
Body weight wasmeasured in fasting participants on weeks 0, 4, 8,
and 12 using a calibrated digital scale (Tanita TCS-WB-3000, UK)
with participants wearing light clothes without shoes. Height was
measured without shoes using a stadiometer to the nearest 0.5 cm.
Systolic and diastolic blood pressures were measured in duplicate
on the left arm after 5min of rest using an automatic blood pres-
sure monitor (UA-767PC Blood Pressure Monitor, A&D Medi-
cal). BMI was calculated as BW (kilogram)/height (square meter).
Waist circumference was measured at the midway point between
the iliac crest and the lowest rib.
Biochemical Analysis
Blood samples were collected at baseline and at end of study
after 10min of rest in the supine position for each participant.
Participants were instructed to avoid all foods, beverages, and
strenuous activity for at least 10 h prior to blood sampling.
Blood was collected into red-top vacutainers with no antico-
agulant and left at room temperature for 30min prior to cen-
trifugation at 4°C for 15min at 1500 g. A blood sample from
fasting participants was also collected into a tube containing
EDTA for analysis of HbA1c. Blood for all other analyses was
collected in plain tubes. Serum glucose, lipid profiles, liver and
renal biochemistry, and C-reactive protein were determined by
using the Hitachi 7070 automatic biochemical analyzer (Hitachi
Ltd, Japan). HbA1c was analyzed using a high-performance
liquid chromatography, ion-exchange chromatography assay
(HLC-723G7, TOSOH, Japan). Insulin was measured using a
well-established radioimmunoassay in the endocrinology labo-
ratory of Tianjin Medical University Metabolic Disease Hospi-
tal. Insulin resistance was estimated by the Homeostasis Model
Assessment Index (HOMA-IR), and was calculated using the fol-
lowing formula: HOMA-IR= [fasting insulin (μU/mL) fasting
plasma glucose (mmol/L)]/22.5; HOMA-β-cell= fasting insulin
(μU/mL)/[fasting plasma glucose (mmol/L)  3.5] (20).
Satiety
A visual analog scale (VAS), as described by Flint et al. (21),
whichwas 100mm in length with words anchored at each end that
expressed the most-positive and most-negative rating, was used
to answer questions regarding subjective feelings of hunger and
satiety. Questionnaires were completed at 10 fixed time points,
respectively, just before and after the Inzone Preload during the
study period. For example, the question was “How hungry do you
feel at thismoment,” whichwas anchored at the low endwith “very
hungry” and with the opposing term “not at all” at the high end.
Incremental areas under the percent score time curves (AUCs)
from 0 to 2 h were calculated using the linear trapezoidal method.
Adverse Event and Safety
All subjects had the possibility to report spontaneous adverse
events (AEs) on all visiting days, which took place every second
week during thewhole study. AEswere documented and graded as
mild, moderate, or severe conditions. Aside from AEs, other sur-
rogate laboratory safety endpoints monitored were serum nitro-
gen and creatinine, hepatic transaminases (alanine aminotrans-
ferase and aspartate aminotransferase), and blood routine test.
Statistical Methods
Normally distributed data are expressed as mean SD and non-
normally distributed data median or as numbers and percent-
ages. Non-normally distributed data were log-transformed for use
with parametric statistics. Paired t-test was used to compare the
differences in clinical characteristics between baseline and after
intervention. Unpaired t-tests were also used to compare baseline
variables between Responders and Non-responders in subjects
treated with the Inzone Preload. A multiple linear regression
model was prepared to simultaneously evaluate the effects of
the factors (age, BMI, duration of diabetes, and baseline HbA1c
and HOMA-β) on 2 h-BG changes. The statistical analyses were
performed using SPSS windows version 18.0, and p value <0.05
was considered to be of statistical significance.
Results
Participant Characteristics
Thirty participants were enrolled in the study between February
and September 2013 and a total of 27 completed the study. The
reasons for withdrawals were: one disliked the study treatment
powders and two went abroad for personal reasons. Of the 27
completing participants, 17 were males and 10 were females.
Participants had amean of 6.3 3.6 years since diagnosis of type 2
diabetes. The average age of participants was 54.8 7.8 years, with
an average BMI of 26.5 3.4 kg/m2. Baseline characteristics of the
study participants are shown in Supplement S1 in Supplementary
Material. At baseline, 83.3% (25/30) of the patients were taking
two or more medications, the most widely used combination was
metformin and repaglinide, followed bymetformin and gliclazide.
Three percent (4/30) of the patients were using basal insulin.
Changes in Parameters Relating to Glucose
Metabolism Following 12-Week Inzone
Preload Intervention
After 12weeks of the Inzone preload intervention, 2 h-BG was
reduced from 12.2 1.2mmol/L at baseline to 10.5 2.0mmol/L,
mean change of 1.7mmol/L (95%CI of 0.6–2.4, p= 0.013), but no
significant changes were observed in FPG; Reductions in 2 h-BG
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were found near maximal at week 4, with modest progressive
reductions and no apparent plateau observed through the 12-week
period. Eighteen (67%) of the patients achieved the target 2 h-BG
reduction of 1.9mmol/L at the end of the study. Overall HbA1c
values were reduced from 7.4 0.2% at baseline to 7.1 0.2% at
12weeks, with an average relative change of 5.4% (95%CI 1.0–6.2,
p< 0.05). Neither the HOMA-IR nor HOMA-β was significantly
changed following the 12-week Inzone preload (HOMA-IR from
baseline 4.3 1.5 to 4.2 2.1, p= 0.670; HOMA-β from baseline
56.4 20.2 to 60.3 24.0, p= 0.824) in all the subjects (Table 1).
Changes in Parameters Relating to Serum Lipids
and CRP Following 12-Week Inzone Preload
Intervention
Compared with baseline values, overall serum total cholesterol
and LDL concentrations were significantly reduced by 0.5 0.2
and 0.3 0.1mmol/L, respectively. Changes in mean serum
triglycerides from 1.7 0.6 to 1.8 0.8mg/dL did not reach sig-
nificant levels (p= 0.644). In addition, no significant changeswere
observed in HDL-c during the intervention period (p= 0.724).
Interestingly, the levels of serum CRP, a marker of clinical
inflammation, were significantly reduced from baseline following
12weeks Inzone Preload intervention, with mean changes from
1.5 1.4 to 0.7 0.7mg/L (p= 0.047) (Table 1).
Changes in Anthropometric Measures Following
12-Week Inzone Preload Intervention
At the end of the 12-week intervention period, BW was reduced
from 76.4 11.5 kg at baseline to 75.5 10.6 kg, mean change
of 0.9 kg (95% CI of  1.9 to 0.7, p= 0.390) (Table 1). Thir-
teen patients (48.1%) lost more than 3% BW during the
intervention phase, from 83.3 12.0 to 80.8 10.7 kg. Three sub-
jects gained weight during the intervention period (79.3 14.4
vs. 80.0 9.4 kg, p= 0.613) and the remaining 11 subjects did
not show any change in weight. Most of the weight loss was
observed during the initial month, with progressive reductions
through week 12 (Supplement S2 in Supplementary Material).
BW reduction was linked to changes in waist circumference
(r= 0.524, p= 0.035). Compared with women, men had a higher
mean baseline BW; however, we found no significant sex differ-
ences for changes in weight (data not shown).
Changes in VAS Ratings of Satiety and Hunger
The Inzone Preload intervention resulted in a significantly higher
postprandial satiety at the onset of the meal (at time point 0min,
30min after preloadwas given) (p= 0.045) and 30min (p= 0.042)
after the habitual breakfast (Figure 1A). The AUCs for satiety
were not significantly larger at any time after Inzone Preload than
habitual breakfast. Regarding the questions on aspects of hunger,
subjects reported a lower level of hunger after the Inzone Preload
than after the habitual breakfast at 0min (p= 0.047) and after
30min (p= 0.352). No differences were observed in the AUCs for
hunger (p= 0.241) (Figure 1B).
Side Effects and Safety
There were few AEs during the study and these were generally
mild. One subject reported mild diarrhea on the initial, but this
phenomenon disappeared after a week, the subject remained com-
pliant throughout the study. There were no significant changes
in the blood routine examination, serum nitrogen and creatinine,
hepatic transaminases compared to those at the baseline (data not
shown).
Identification of Subgroups and Multiple Linear
Regression Analysis
It was clear from the data above that the response to Inzone
treatment varied between individuals. In an attempt to analyze
data further, we attempted to separate individuals responding
from non-responders using 2 h-BG measurements. A lowering of
2 h-BG1.9mmol/L (22) was used as a cut-off and this separated
67% of the subjects into one group termed responders (n= 19)
and another group called non-responders (n= 8) (Table 2). In the
responding group, reduction of 2 h-BG was near maximal at week
4, with modest progressive reductions and no apparent plateau
TABLE 1 | Characteristics of patients (mean SD) at baseline and after 12weeks of preload testing (n= 27).
Characteristics Baseline After 12weeks Mean changes from
baseline (95% CI)
p Value
FBG (mmol/L) 7:2 0:8 7:0 0:6  0.2 ( 0.4 to 0.2) 0.714
2 h-BG (mmol/L) 12:2 1:2 10:5 2:0  1.7 ( 0.6 to 2.5) 0.013
FPI (mIU/L) 18:8 13:5 16:9 10:3  1.9 ( 3.2 to 0.4) 0.390
HbA1c (%) 7:4 0:3 7:1 0:2  0.3 ( 0.5 to  0.1) 0.032
Weight (kg) 76:4 11:5 75:5 10:6  0.9 ( 1.9 to 0.7) 0.604
BMI (kg/m2) 26:5 3:4 26:4 3:5  0.1 ( 0.1 to 0.1) 0.672
WC (cm) 94:2 10:5 93:410:1  0.8 ( 1.4 to 0.5) 0.529
TG (mmol/L) 1:7 0:6 1:8 0:8 0.1 ( 0.3 to 0.2) 0.644
TC (mmol/L) 4:8 0:9 4:30:8  0.5 ( 0.2 to  0.7) 0.022
HDL-c (mmol/L) 1:2 0:2 1:2 0:3 0.0 ( 0.1 to 0.2) 0.517
LDL-c (mmol/L) 2:8 0:6 2:50:4  0.3 ( 0.1 to  0.5) 0.018
CRP (mg/L) 1:5 1:4 0:7 0:7  0.7 ( 0.2 to  1.1) 0.047
HOMA-IR 4:3 1:5 4:2 2:1  0.1 ( 0.2 to 0.3) 0.670
HOMA-β 56:4 20:2 60:3 24:0 2.9 (1.1–11.3) 0.824
Normally distributed data expressed as meanSD and non-normally distributed data were log-transformed for use with parametric statistics. FBG, fasting blood glucose; 2 h-BG,
postprandial 2 h blood glucose; FPI, fasting insulin; TG, triglyceride; TC, total cholesterol; LDL-C, low density lipoprotein-cholesterol; HDL-c, high density lipoprotein-cholesterol; CRP,
c-reactive protein; HOMA-IR= fasting glucose (mg/dL) fasting insulin (U/mL)/405; 95% CI, lower 95% confidence interval limit, upper 95% confidence interval limit. HOMA-
β=360 FPI (μIU/mL)/[FPG (mg/dL)  63].
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FIGURE 1 | (A,B) Effects of preload on satiety (A) and hunger (B). Mean
visual analog scale (VAS) subjective scores for satiety (A) and hunger (B) for
habitual breakfast. Habitual breakfast is indicated by -- and Preload before
habitual breakfast by -N-. Inserts: area under the curve histograms for
0–120min are shown, habitual breakfast (open bars), and preload before
habitual breakfast (filled bars). The time-by-interaction was statistically
significant for satiety (p<0.05, 0–120min).
observed through week 12 (Figure 2). In the responding group,
a reduced BW was seen in 13 patients after 8weeks and this was
maintained during the study (Supplement S2 in Supplementary
Material). A multiple regression analysis was performed to eval-
uate the independent factors that might predict 2 h-BG changes.
A weak but significant linear correlation was found that shorter
duration of diabetes, higher HOMA-β level and greater reduction
in BW were significantly correlated with 2 h-BG reduction, but
BMI, baseline HbA1c were insignificant factors (Table 3).
Discussion
To our knowledge, this study is first to investigate the long-
term metabolic effects of a macro-nutrient preload in T2DM.
No adverse effects were noted among the 27 subjects who com-
pleted the study. As a dietary intervention, a majority of Inzone
Preload-treated T2DM patients responded by lowing 2 h-BG,
HbA1c, total cholesterol and LDL, and CRP at the end of 12-week
treatment period. It was also noteworthy that significant weight
loss occurred in 13 of the 27 subjects (48.1%) in the study. Other
studies have evaluated the metabolic effects of different types of
preloads, and a common feature of those studies is the testing of
simple ingredients and short observation times. In contrast, our
study concerns a macro-nutrient preload mix and effects were
evaluated during a relatively long time. The components of the
Inzone Preload are a mix of natural food ingredients, and in
addition to high protein and low carbohydrate, the preload also
contains polyunsaturated fatty acids, dietary fiber, and vitamin C,
which have documented health benefits (23–26).
Our study showed that mean 2 h-BG and HbA1c levels
are significantly decreased by preload treatment amounting to
1.7mmol/L and 0.3%, respectively. This was observed in a major-
ity of subjects whereas some patients responded poorly to the
treatment. The reason why not all patients responded is not clear
but there were differences in T2D characteristics within the group
and the compliancy to treatment was not monitored. The present
study supports previous findings that protein-enriched and low-
GI diets can reduce 2 h-BG and HbA1c (16, 17). However, this
effect on 2 h-BG lowering was not observed in all subjects in
our study where 19 subjects (70.4%) displayed a decrease in 2 h-
BG. We stratified the subjects into two subgroups to analyze
this phenomenon. Compared to the non-responding subgroup
at baseline, the responding subgroup had a shorter duration of
diabetes, higher HOMA-β level, indicating that Inzone preload
may be more beneficial in less advanced diabetes. A decrease
in postprandial glucose by a macro-nutrient preload might be
explained by the Incretin response where increased GLP-1 can
affect plasma insulin and insulin sensitivity (27). Our data also
suggest that preload induced changes in 2 h-BG levels positively
correlate with weight loss. Weight loss can induce 2 h-BG reduc-
tions through improving insulin resistance (28). The perceived
satiety increase observed in this study can be another reason for
the postprandial glycemia reduction, since postprandial glycemia
is directly associated with appetite (29, 30).
High-protein and low-GI diets can be effective in weight con-
trol of obese subjects (31) as well as in T2DM patients (31–33).
In this study, BW and waist circumference tended to decrease at
the end of the 12-week period, although not reaching statistical
significance. However, 13 (48.1%) lost weight with a mean change
of 1.7 kg (3% weight loss) andmaintained progressive reduction
during the intervention phase. The relatively small sample size
together with short intervention period might have limited our
ability to detect significantweight loss.Weight reduction inT2DM
patients can be a challenge (34), but even a modest weight reduc-
tion of <5% is of clinical importance, since glycemic metabolism
and cardiovascular disease risk factors improved with net weight
loss of as little as 2–5% in persons with T2DM (35). Possible
explanations for weight loss related to intake of proteins include a
rise in thermic effects (32, 36, 37) and energy intake reduction due
to the increased satiety (31, 38), as satiety is an important factor in
the regulation of food intake and in the control of weight (28).
Low-GI or protein diets can have positive effect on blood lipids
(39–42), but the combination of low-GI and high-protein diets
on blood lipids are somewhat controversial. In a 28-day high-
protein low-GI diet intervention program, total cholesterol and
LDL cholesterol were significantly reduced (43). But in another
study, these lipid parameters did not change after 4weeks of high-
protein low-GI diets intervention (27). Our results suggest that
Inzone Preload reduces total cholesterol and LDL cholesterol.
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TABLE 2 | Baseline and change of biochemical and clinical variables during the study period (end of the study minus baseline) for the Responders group
and Non-responders group.
variables Responders (n= 19) Non-responders (n= 8) p Value
Baseline Change Baseline Change
Age 54.0 7.8 – 56.06.5 – 0.064
Duration of diabetes (years) 4. 33.6 – 7.62.7 – 0.042
Weight (kg) 73.411.5  1.60.3 76.510.6  0.10.2 0.011
BMI (kg/m2) 26.26.4 0.10.1 26.93.1 0.00.1 0.587
FBG (mmol/L) 7.01.1  0.30.2 7.41.0  0.20.1 0.882
2 h-BG (mmol/L) 12.01.2  2.20.9 12.51.8  0.70.3 0.007
HbA1c (%) 7.30.8  0.40.2 7.71.1  0.10.1 0.048
TG (mmol/L) 1.50.6 0.10.2 1.90.6 0.10.2 0.330
TC (mmol/L) 4.60.9  0.60.2 5.00.8  0.50.4 0.587
HDL-c (mmol/L) 1.20.3 0.10.1 1.00.3 0.00.1 0.724
LDL-c (mmol/L) 2.70.7  0.30.3 3.00.8  0.30.2 0.936
CRP (mg/L) 1.41.4  1.10.4 1.81.6  0.20.3 0.021
HOMA-IR 4.12.5  0.60.2 4.93.1  0.20.4 0.342
HOMA-β 56.420.2 10.53.6 30.324.0 6.44.7 0.572
Normally distributed data expressed as meanSD and non-normally distributed data were log-transformed for use with parametric statistics.
FIGURE 2 | Changes in postprandial glucose throughout the study. A
lowering of 2 h-BG of 1.9mmol/L was used as a cut-off separating 67% of
the subjects as responders. Responders (n= 19) are indicated with --.
Non-responders (n=8) are indicated with -N-.
Another important finding in our study is that the Inzone Preload
significantly reduced the inflammatory marker CRP, which is rel-
evant in consideration to the connections between inflammation
and T2D. The results reported here are consistent with other pub-
lished interventions demonstrating that low-glycemic and high-
protein diets reduce serum CRP (44). The CRP reduction may
not only be due to glucose improvement (45) but may also involve
polyunsaturated fatty acids and dietary fiber in the preload, since
most of these components are known to reduce CRP (46–48). It
should be emphasized that the present study concerns the con-
cept of preload, which is different from complete dietary change.
There are certain advantages with the preload concept because the
challenges to completely change diet are not needed and also that
preload effects can be studied much in the same way as regular
drug testing.
Our study had several limitations. First, the study was not a
randomized clinical trial. Second, the study was performed in
outpatient clinic, so we could not monitor diets and other life style
TABLE 3 |Multiple regression analysis of the potential variables for predict-
ing changes in 2h-BG level as dependent variables.
Variable β p Value
BMI (kg/m2) 0.046 0.263
Duration of diabetes  0.511 0.031
Baseline HbA1c (%) 0.499 0.451
Δ Weight (kg) 0.964 0.044
HOMA-β 0.240 0.039
HOMA-IR 0.610 0.347
Beta is the standardized partial regression coefficient of multiple linear regression analysis.
factors of our subjects throughout the study period, which might
have impacted study outcomes. Finally, the relatively small sample
size and short duration of the study limited our power to detect
differences in many metabolic parameters.
In summary, the results of this study support our hypothesis
that Inzone preload improves glycemic control and have favor-
able effects on weight and serum lipids in patients with T2DM.
Despite some potential limitations, our preliminary study offers
new insights into patients with sustained poor 2 h-BG control who
might benefit from this type of interventions. As a dietary strat-
egy, the Inzone preload, consisting of polyunsaturated fatty acids,
dietary fiber from natural food ingredients has unique advantages
in the lipid and inflammation improvement.We recommend large
studies over a longer period of time to investigate the longitudinal
effects of the Inzone preload on diabetic patients.
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